# Francesco Prattichizzo

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 77 papers | 2,493 citations | 31 h-index | 48 g-index |
| 82 ext. papers | 3,378 ext. citations | 8 avg, IF | 5.75 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 77 | MitomiRs in human inflamm-aging: a hypothesis involving miR-181a, miR-34a and miR-146a. *Experimental Gerontology*, **2014**, 56, 154-63 | 4.5 | 145 |
| 76 | Inflammageing and metaflammation: The yin and yang of type 2 diabetes. *Ageing Research Reviews*, **2018**, 41, 1-17 | 12 | 117 |
| 75 | The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. *Nutrients*, **2017**, 9, | 6.7 | 116 |
| 74 | Toll like receptor signaling in "inflammaging": microRNA as new players. *Immunity and Ageing*, **2013** , 10, 11 | 9.7 | 101 |
| 73 | Anti-senescence compounds: A potential nutraceutical approach to healthy aging. *Ageing Research Reviews*, **2018**, 46, 14-31 | 12 | 97 |
| 72 | Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. *Cytokine and Growth Factor Reviews*, **2020**, 53, 33-37 | 17.9 | 84 |
| 71 | MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. *Oncotarget*, **2015**, 6, 35372-82 | 3.3 | 79 |
| 70 | Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. *Aging*, **2014**, 6, 771-87 | 5.6 | 78 |
| 69 | Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. *Redox Biology*, **2018**, 15, 170-181 | 11.3 | 69 |
| 68 | "Inflammaging" as a Druggable Target: A Senescence-Associated Secretory Phenotype-Centered View of Type 2 Diabetes. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 1810327 | 6.7 | 68 |
| 67 | T Cells: Warriors of SARS-CoV-2 Infection. *Trends in Immunology*, **2021**, 42, 18-30 | 14.4 | 65 |
| 66 | Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. *Clinical Epigenetics*, **2015**, 7, 56 | 7.7 | 64 |
| 65 | Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells. *Journal of Extracellular Vesicles*, **2020**, 9, 1725285 | 16.4 | 63 |
| 64 | Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2515-2522 | 6.7 | 62 |
| 63 | Anti-TNF-□treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. *Oncotarget*, **2016**, 7, 11945-58 | 3.3 | 57 |
| 62 | Anti-inflammatory effect of ubiquinol-10 on young and senescent endothelial cells via miR-146a modulation. *Free Radical Biology and Medicine*, **2013**, 63, 410-20 | 7.8 | 56 |
| 61 | Where Metabolism Meets Senescence: Focus on Endothelial Cells. *Frontiers in Physiology*, **2019**, 10, 1523 | 4.6 | 56 |

| | | | |
|---|---|---|---|
| 60 | Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. *Ageing Research Reviews*, **2018**, 48, 87-98 | 12 | 54 |
| 59 | Exosome-based immunomodulation during aging: A nano-perspective on inflamm-aging. *Mechanisms of Ageing and Development*, **2017**, 168, 44-53 | 5.6 | 51 |
| 58 | Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. *Cardiovascular Diabetology*, **2018**, 17, 105 | 8.7 | 47 |
| 57 | Why is hyperglycaemia worsening COVID-19 and its prognosis?. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1951-1952 | 6.7 | 46 |
| 56 | Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. *Diabetes, Obesity and Metabolism*, **2016**, 18, 855-67 | 6.7 | 46 |
| 55 | The link between diabetes and atherosclerosis. *European Journal of Preventive Cardiology*, **2019**, 26, 15-24 | 3.9 | 43 |
| 54 | Type 2 Diabetes: How Much of an Autoimmune Disease?. *Frontiers in Endocrinology*, **2019**, 10, 451 | 5.7 | 42 |
| 53 | The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. *Endocrine*, **2017**, 56, 509-520 | 4 | 41 |
| 52 | Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D. *Cardiovascular Diabetology*, **2019**, 18, 18 | 8.7 | 40 |
| 51 | Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. *European Journal of Preventive Cardiology*, **2019**, 26, 73-80 | 3.9 | 39 |
| 50 | Senescence associated macrophages and "macroph-aging": are they pieces of the same puzzle?. *Aging*, **2016**, 8, 3159-3160 | 5.6 | 36 |
| 49 | Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs. *Mechanisms of Ageing and Development*, **2014**, 143-144, 1-8 | 5.6 | 35 |
| 48 | Leukocyte telomere length and mortality risk in patients with type 2 diabetes. *Oncotarget*, **2016**, 7, 50835-50844 | 5.5 | 33 |
| 47 | miR-21 and miR-146a: The microRNAs of inflammaging and age-related diseases. *Ageing Research Reviews*, **2021**, 70, 101374 | 12 | 30 |
| 46 | Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?. *Mediators of Inflammation*, **2017**, 2017, 2309034 | 4.3 | 27 |
| 45 | Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1696-1700 | 6.7 | 25 |
| 44 | Extracellular vesicles circulating in young organisms promote healthy longevity. *Journal of Extracellular Vesicles*, **2019**, 8, 1656044 | 16.4 | 25 |
| 43 | NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 24 |

| | | | |
|---|---|---|---|
| 42 | Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools. *Current Drug Targets*, **2016**, 17, 388-97 | 3 | 20 |
| 41 | Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. *Theranostics*, **2021**, 11, 1031-1045 | 12.1 | 20 |
| 40 | Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. *Metabolism: Clinical and Experimental*, **2020**, 110, 154308 | 12.7 | 19 |
| 39 | CD31 Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. *Diabetes*, **2021**, 70, 240-254 | 0.9 | 19 |
| 38 | The mitomiR/Bcl-2 axis affects mitochondrial function and autophagic vacuole formation in senescent endothelial cells. *Aging*, **2018**, 10, 2855-2873 | 5.6 | 18 |
| 37 | Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. *Cell Death and Disease*, **2013**, 4, e594 | 9.8 | 16 |
| 36 | Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 15 |
| 35 | MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab. *British Journal of Dermatology*, **2018**, 179, 787-789 | 4 | 15 |
| 34 | Pleiotropic effects of polyphenols on glucose and lipid metabolism: Focus on clinical trials. *Ageing Research Reviews*, **2020**, 61, 101074 | 12 | 14 |
| 33 | Chemical composition and in vitro anti-inflammatory activity of Vitis vinifera L. (var. Sangiovese) tendrils extract. *Journal of Functional Foods*, **2016**, 20, 291-302 | 5.1 | 13 |
| 32 | Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM. *Oncotarget*, **2017**, 8, 93338-93348 | 3.3 | 13 |
| 31 | Novel insights into the regulation of miRNA transcriptional control: implications for T2D and related complications. *Acta Diabetologica*, **2018**, 55, 989-998 | 3.9 | 12 |
| 30 | Inflamm-aging microRNAs may integrate signals from food and gut microbiota by modulating common signalling pathways. *Mechanisms of Ageing and Development*, **2019**, 182, 111127 | 5.6 | 12 |
| 29 | Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. *Oncotarget*, **2018**, 9, 8898-8910 | 3.3 | 10 |
| 28 | The pleiotropic roles of leptin in metabolism, immunity, and cancer. *Journal of Experimental Medicine*, **2021**, 218, | 16.6 | 10 |
| 27 | Glycaemic management in diabetes: old and new approaches. *Lancet Diabetes and Endocrinology,the*, **2021**, | 18.1 | 9 |
| 26 | Two drugs are better than one to start T2DM therapy. *Nature Reviews Endocrinology*, **2020**, 16, 15-16 | 15.2 | 9 |
| 25 | Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes. *Diabetologia*, **2020**, 63, 2699-2712 | 10.3 | 9 |

| | | | |
|---|---|---|---|
| 24 | Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis. *Diabetes/Metabolism Research and Reviews*, **2021**, e3476 | 7.5 | 9 |
| 23 | Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. *Metabolism: Clinical and Experimental*, **2021**, 120, 154799 | 12.7 | 9 |
| 22 | Effect of time and titer in convalescent plasma therapy for COVID-19. *IScience*, **2021**, 24, 102898 | 6.1 | 8 |
| 21 | Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. *Cardiovascular Diabetology*, **2021**, 20, 218 | 8.7 | 7 |
| 20 | Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. *Immunity*, **2021**, 54, 1543-1560.e6 | 32.3 | 7 |
| 19 | Pharmacological management of COVID-19 in type 2 diabetes. *Journal of Diabetes and Its Complications*, **2021**, 35, 107927 | 3.2 | 7 |
| 18 | Response to: Letter to the Editor on "Bonaf□M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev" by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella. *Cytokine and Growth Factor Reviews*, **2021**, 58, 141-143 | 17.9 | 7 |
| 17 | Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs. *Scientific Reports*, **2020**, 10, 21782 | 4.9 | 6 |
| 16 | Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. *Frontiers in Endocrinology*, **2020**, 11, 254 | 5.7 | 5 |
| 15 | DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2021**, 14, 1519-1531 | 3.4 | 5 |
| 14 | Variability of risk factors and diabetes complications. *Cardiovascular Diabetology*, **2021**, 20, 101 | 8.7 | 5 |
| 13 | The Activity of L. Essential Oil on Inflammation. *Journal of Medicinal Food*, **2018**, 21, 1238-1243 | 2.8 | 5 |
| 12 | Ageing as a druggable process: Moving forward. *EBioMedicine*, **2019**, 40, 15-16 | 8.8 | 4 |
| 11 | One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study. *BMJ Open Diabetes Research and Care*, **2020**, 8, | 4.5 | 4 |
| 10 | Tackling the pillars of ageing to fight COVID-19. *The Lancet Healthy Longevity*, **2021**, 2, e191 | 9.5 | 4 |
| 9 | Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register. *Cardiovascular Diabetology*, **2021**, 20, 173 | 8.7 | 4 |
| 8 | Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms.. *Journal of Clinical Medicine*, **2022**, 11, | 5.1 | 4 |
| 7 | Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes.. *Nature Communications*, **2022**, 13, 2318 | 17.4 | 4 |

| | | | |
|---|---|---|---|
| 6 | Positioning newer drugs in the management of type 2 diabetes. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 138-139 | 18.1 | 3 |
| 5 | CD4 T-Cell Activation Prompts Suppressive Function by Extracellular Vesicle-Associated MicroRNAs. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 753884 | 5.7 | 2 |
| 4 | Senescent macrophages in the human adipose tissue as a source of inflammaging.. *GeroScience*, **2022**, 1 | 8.9 | 2 |
| 3 | Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.. *Cellular and Molecular Life Sciences*, **2022**, 79, 273 | 10.3 | 2 |
| 2 | HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.. *Cardiovascular Diabetology*, **2022**, 21, 13 | 8.7 | 1 |
| 1 | The beneficial effects (on cardio-renal system) of glucose-lowering agents with caloric-restriction mimetic properties are subtractive rather than additive. *Diabetes Research and Clinical Practice*, **2020**, 163, 108030 | 7.4 | |